$115 Million

Vera Therapeutics, Inc.

Follow-on Offering

Bookrunner, February 2023

Vera Therapeutics, Inc.

Vera Therapeutics, Inc. (“Vera”) is a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases. Vera’s lead product candidate, atacicept, is a self-administered fusion protein that blocks both B lymphocyte stimulator (BLyS) and a proliferation-inducing ligand (APRIL), and is currently being evaluated for the treatment of immunoglobulin A nephropathy (IgAN). The Company plans to initiate a pivotal Phase 3 clinical trial for atacicept in the first half of 2023. Vera is also developing MAU868, a monoclonal antibody designed to treat BK Virus, a polyomavirus that can have devastating consequences in certain settings such as kidney transplant and hematopoietic stem cell transplant.